Abstract Tyrosine kinase inhibitors (TKi) hold promise as a treatment for a variety of disorders ranging from those in oncology to diseases thought as immune mediated. Tyrphostin AG490 is a potent Jak-Stat TKi shown effective in the prevention of allograft transplant rejection, experimental autoimmune disease, as well as the treatment of cancer. However, given its ability to modulate this important but pleiotropic intracellular pathway, we thought that it is important to examine its effects on glucose metabolism and expression of major transcription factors and adipokines associated with insulin insensitivity and diabetes. We investigated the metabolic effects of AG490 on glucose levels in vivo using an animal model of diabetes, nonobese diabetic (NOD) mice, and transcription factor expression through assessment of human adipocytes. AG490 treatment of young nondiabetic NOD mice significantly reduced blood glucose levels (p00.002). In vitro, treatment of adipocytes with rosiglitazone, an insulin sensitizer that binds to peroxisome proliferator-activated receptor (PPAR) receptors and increases the adipocyte response to insulin, significantly increased the expression of the antidiabetic adipokine adiponectin. Importantly, the combination of rosiglitazone plus Tyrphostin AG490 further increased this effect and was specifically associated with significant upregulation of Cenhanced binding protein (C/EBP) (p<0.0001). In terms of the mechanism underlying this action, regulatory regions of the PPARγ, ADIPOQ, and C/EBP contain the Stat5 DNAbinding sequences and were demonstrated, by gel shift experiments in vitro. These data suggest that blocking JakStat signaling with AG490 reduces blood glucose levels and modulates the expression of transcription factors previously associated with diabetes, thereby supporting its potential as a therapy for this disease.
Tyrosine kinase inhibitors (TKi) represent a promising class of drugs for the treatment of disease. Among those most promising and advanced are those seeking to prevent transplant rejection Changelian et al. 2003; Higuchi et al. 2005; Saemann et al. 2004; Stepkowski et al. 2001 Stepkowski et al. , 2002 and providing an efficacious treatment for a variety of cancers (Baselga 2006; Hagerkvist et al. 2007; Santos and Verstovsek 2011) . This hope has also recently been extended to the field of autoimmune disease where promising preclinical data have been observed in mouse models of multiple sclerosis (Crespo et al. 2011) , intestinal inflammation (Sidhu et al. 2011) , experimental autoimmune encephalomyelitis (Bright et al. 1999; Constantin et al. 1998 Constantin et al. , 1999 , and type 1 diabetes (T1D) (Louvet et al. 2008; Mokhtari and Welsh 2010) . Indeed, with respect to this latter disorder, oral administration of sunitinib (Sutent) and imatinib (Gleevec), two TKi, has been shown to prevent as well as reverse T1D in nonobese diabetic (NOD) mice (Louvet et al. 2008) . Tyrphostin AG490, another form of TKi, is a potent inhibitor of the Jak-Stat signaling pathway (Goncalves et al. 2010 ) and, reportedly, more active as a Jak2 inhibitor than Jak3 (Luo and Laaja 2004) . Additionally, Tyrphostin AG490 has no impact on membrane-associated kinases such as Lyn, Btk, Syk, Src, and Zap70 Meydan et al. 1996) , suggesting that it is not a general kinase inhibitor Luo and Laaja 2004; O'Shea 1997; O'Shea et al. 2004; Wang et al. 1999) . With respect to specific effects of Tyrphostin AG490 on the immune response, it has been noted to block IL-12-mediated T cell proliferation, inhibit phosphorylation of Stat3, decrease IFN-γ production mediated by IL-12 (Bright et al. 1999) , and inhibit the differentiation of antigen-specific Th1 cells in vivo (Changelian et al. 2003) . Recently, we demonstrated that in vivo administration of Tyrphostin AG490 prevents and reverses T1D in NOD mouse (Davoodi-Semiromi et al. 2012a, b) , suggesting that this drug possesses immunomodulating properties; however, potential metabolic effects (i.e., those separate of immunological in nature) of this compound have not been described. Compelling evidence demonstrates that the Jak-Stat signaling pathway plays a critical role in adipocyte development and function (Baugh et al. 2007; Coulter and Stephens 2006; Floyd et al. 2007; Richard and Stephens 2011; Stewart et al. 2011; White et al. 2007; White and Stephens 2010a, b; Zhang et al. 2011) . Therefore, we investigated the effects of Tyrphostin AG490 on glucose levels in vivo and on several major transcription factors associated with diabetes, namely, peroxisome proliferator-activated receptor gamma 1 (PPARγ1), PPARγ2, C-enhanced binding protein (C/EBP), activating protein-2, adiponectin, and two members of the STAT family, Stat5 and Stat3. These assessments were performed both in vitro via mRNA analysis as well as at a protein level, both involving human adipocytes. The resulting data suggest that Tyrphostin AG490 regulates glucose metabolism in vivo and modifies the molecular activation of diabetes-related transcription genes favoring increased insulin sensitivity, leading to what would be considered improved diabetes status. Our data also suggest that the Jak-Stat signaling pathway negatively regulates gene expression of key factors playing a vital role in glucose metabolism.
With respect to our experimental plan, female NOD/LtJ mice were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in ventilated cages in a specific pathogenfree facility at the University of Florida. All mice were maintained and handled in accordance with the University of Florida Institutional Animal Care and Use Committee. Tyrphostin AG490 (EMD Chemicals, Gibbstown, NJ), 5 mg, was initially dissolved in sterile DMSO (EMD Chemicals) and brought to final volume by sterile phosphate-buffered saline (PBS). One vial of compound containing 5 mg of AG490 was injected into five mice (1 mg/mouse) via intraperitoneal (i.p.) route. Mice (4 weeks of age) were treated three times per week for five consecutive weeks and were euthanized 1 week after the last injection at week 10. Concentration of Tyrphostin AG490 in all in vitro studies was 10 μM. Rosiglitazone was purchased from Cayman Chemical (San Francisco, CA), and a final concentration of 2 μM was used in all experiments described herein. Simpson-Golabi-Behmel syndrome (SGBS) cell culture and adipocyte differentiation were performed as described elsewhere (Fischer-Posovszky et al. 2008; Wabitsch et al. 2001) . Fully differentiated adipocytes were starved from 3FC medium for 1-3 h and then left either untreated (control), treated with rosiglitazone alone, or with Tyrphostin AG490 plus rosiglitazone for 0.5, 2, and 16 h (overnight) under 3FC conditions.
Real-time TaqMan gene expression analyses were performed on total RNA extracted from SGBS cell cultures using RNAeasy kits (QIAGEN) and converted to cDNA using High-Capacity cDNA Reverse Transcription kits (Applied Biosystems) followed by PCR amplification using a 7300 Applied Biosystems PCR machine. Electrophoresis mobility shift assays (EMSAs) were performed as described elsewhere (Davoodi-Semiromi et al. 2004 , 2007a . All analyses for statistical significance were performed using Prism 5.0 software (GraphPad Software Inc., La Jolla, CA). Realtime data [ddCt (Relative Quantitation)] were analyzed using integrated SDS software, V1.4.0 (Applied Biosystems) and RQ value (fold change) as described elsewhere (Davoodi-Semiromi and Cooper-Dehoff 2011) with p value less than 0.05 considered statistically significant.
Prediabetic NOD mice were treated either with Tyrphostin AG490 (1 mg/mouse) or vehicle (DMSO+PBS) three times per week for five consecutive weeks, and body weight and blood glucose level were measured at least one to two times/ week. As shown in Fig. 1a , b (n015/group), i.p. administration of Tyrphostin AG490 had no effect on body weight gain or loss; however, blood glucose values were significantly lower in Tyrphostin AG490-treated NOD mice at week 8 (p00.0021, n015, Fig. 1 ) when compared with DMSOtreated mice (n014), suggesting metabolic effects of this compound on glucose metabolism. As noted previously, we recently demonstrated successful prevention and reversal of T1D in NOD mice (Davoodi-Semiromi et al. 2007b , 2012a , opening the possibility that the Jak-Stat signaling pathway has a negative effect on glucose metabolism in situations of ongoing inflammation; yet, this notion required investigation.
An additive and significant upregulation of PPARγ2, but not PPARγ1, at both mRNA and protein level was observed when SGBS cells were treated with rosiglitazone and Tyrphostin AG490 (see Fig. 2b, d) ; however, this effect was quenched when the cells were treated for a longer period of time (16 h). Sustained upregulation of PPARγ at protein level was observed by rosiglitazone when the cells were treated for 16 h (Fig. 2d) , and combination of rosiglitazone plus Tyrphostin AG490 slightly increased expression of PPARγ2 when compared to the control. These data suggest that PPARγ2 is an early responding gene and, second, that the Jak-Stat signaling pathway negatively regulates expression of PPARγ2 but not PPARγ1. As shown in Fig. 3 , SGBS cells treated with rosiglitazone alone, or a combination of rosiglitazone plus Fig. 1 Administration of Tyrphostin AG490 reduces blood glucose level in prediabetic NOD mice. Female NOD mice (n015) were injected (i.p.) at 4 weeks of age with Tyrphostin AG490 (1 mg/ mouse), while control animals received the same number of injections of the vehicle (DMSO and PBS), three times per week. Blood glucose levels were measured at least twice per week. Blood glucose levels and body weight of Tyrphostin AG490 and DMSO-treated mice at week 8 are shown Tyrphostin AG490, had no effect on expression of C/EBP or the antidiabetic adipokine, adiponectin, within 2 h; however, significant upregulation of adiponectin was observed when SGBS cells were treated either with rosiglitazone or with a combination of rosiglitazone plus Tyrphostin AG490. Furthermore, this was associated with marked upregulation of C/EBP for a longer period of time (see Fig. 3 , right panel). We also examined the effects of these drugs on AP2 gene expression at different time points, with no significant differences observed (data not shown), suggesting that upregulation of adiponectin by rosiglitazone and Tyrphostin AG490 is not mediated via this transcription factor. Since insulin receptors play a major role in diabetes, we also examined the effects of these two drugs, by real-time reverse transcriptase (RT)-PCR, on the expression of insulin receptors at different time points. The combination of rosiglitazone plus Tyrphostin AG490 slightly increased insulin receptor expression, albeit this did not reach statistical significance (data not shown). Taken together, these data suggest that rosiglitazone treatment alone and/or in combination with Tyrphostin AG490 ameliorates expression of adiponectin and is likely mediated via the C/EBP but not through PPARγ1-2. Furthermore, the Jak-Stat signaling pathway negatively regulates expression of adiponectin. Additionally, our data suggest that the PPARγ1 and PPARγ2 genes responded very quickly to stimuli and thus can be considered as early responding genes. However, the other two genes (i.e., AP2 and C/EBP) are late responding genes given their response patterns to stimuli (Supplementary Table 1) .
We reasoned that if expression of PPARγ, ADIPOQ, and C/EBP was regulated by the Jak-Stat signaling pathway, the Stat DNA-binding consensus sequences should be present within the regulatory region of these genes. As shown in Fig. 4a and Supplementary Table 1, the Stat5 DNA-binding sequences were found within the regulatory region of C/EBP, PPARγ, and ADPOQ, respectively. These data suggest that these genes are downstream to the Jak-Stat5. Furthermore, as shown in Fig. 4b , activated Stat5 bound to oligonucleotides containing the Stat5 consensus sequences [TTG(N) 3 CAA] in EMSA experiments. The Stat5/DNA complexes were observed at expected position, and by application of antiStat5 antibody (lane 4), the Stat5/DNA complexes were shifted to higher position (Fig. 4b, lane 4; supershift) , suggesting that the Stat5 contributes in the DNA/protein complex. Nonetheless, addition of anti-Stat5 antibody was unable to lift the entire protein/DNA complex to the supershift position, suggesting that other STAT family members and/or other protein(s) may contribute to formation of this complex. With this observation, further in vitro and in vivo studies are warranted to investigate which of the multiple Stat5 DNA-binding sequences are functionally active.
The STAT family members including Stat3 and Stat5 play crucial roles in differentiation and development of many cell types including those related to adipocyte development. We previously reported the effects of Tyrphostin AG490 on activation of Stat5 (Murawski et al. 2006) . As shown in Fig. 5 , rosiglitazone treatment and/or in combination with Tyrphostin AG490 markedly decreased phosphorylation of Stat5 in adipocytes, with no effect on total Stat5 protein when cells were treated for 30 min (the first two top panels indicate comparison of lanes 2 and 3 versus lane 1). With these observations, one could consider that an antidiabetic property of rosiglitazone is, at least in part, due to inactivation of the Jak-Stat5 signaling pathway. Additionally, rosiglitazone increased activation of the truncated Stat5 when the cells were treated for 30 min (Fig. 5, top panel, lane 2 versus lane 1) , further blocking activation of the Jak-Stat pathway. Truncated Stat5 bound strongly with the DNA (see Fig. 4b ); however, it would not be able to initiate the process of transcription due to the absence of transcription domain (i.e., a dominant negative effect). As expected, addition of Tyrphostin AG490 markedly blocked phosphorylation of Stat5 (Fig. 5, top panel, lane 3 versus lane 1) , and an additive effect was observed when Tyrphostin AG490 was combined with rosiglitazone ( Fig. 5 , top panel, lane 2 versus lane 3). Total Stat5 protein did not change when the cells were treated for 30 min; however, combination of rosiglitazone and Tyrphostin AG490 for longer periods of time had no effect on total Stat3 protein but did change total Stat5 protein levels. Based on our data shown in Fig. 3 Tyrphostin AG490 treatment increases expression of adiponectin, and this is associated with upregulation of C/EBP in SGBS. Differentiated adipocytes were left untreated (control) and/or were treated with rosiglitazone alone or with a combination of rosiglitazone plus AG490 for various periods of time. Real-time TaqMan gene expression of two independent cell culture experiments and at least two independent real-time experimental data sets are shown Fig. 5 , longer treatment of adipocytes (i.e., 16 h) with rosiglitazone and/or in combination with Tyrphostin AG490 ameliorates the truncated form of the activated Stat3 similar to what was observed for the Stat5 (see Fig. 5, top panel) . The phosphorylated form of the Stat3 was very low under conditions used in our experiments, and drug treatment had little or no effect on total Stat3 gene expression.
The Jak-Stat signaling pathway is the most important signaling pathway for transduction of signals from the cell surface to the nucleus (Ghoreschi et al. 2009; Ihle 1996; Imada and Leonard 2000; O'Shea et al. 2005) . Based on our observations and those of others, we believe that this signaling pathway has more roles in the pathogenesis and/or treatment of autoimmune diseases, transplantation, and cancer than currently appreciated. Our studies also suggest that the prevention and reversal of T1D observed in our recent studies involving Tyrphostin AG490 treatment of NOD mice were achieved via regulation of both metabolic and immune parameters (Davoodi-Semiromi et al. 2012a, b) .
The presence of the multiple Stat5 DNA-binding consensus sequences within the regulatory region of PPARγ, ADIPQ, and C/EBP also appear clinically relevant. Two studies demonstrated that administration of troglitazone, a PPARγ agonist, significantly delayed the onset of T1D in Complementary oligonucleotides were used to make doublestranded DNA, were endlabeled, and used in EMSA experiments as described in the materials and methods. Lane 1, no protein, probe only; lane 2, unactivated Stat5; lane 3, activated Stat5 (shift complexes); lane 4, activated Stat5 (supershifted complexes). This experiment represents one of at least three independent experiments with consistent results. Ab, antibody; Trn, truncated; NS, nonspecific; FP, free-probe. Note: These figures (a, b) are intended to be in color online and black and white in print NOD mice (Augstein et al. 2003; Beales et al. 1998) , an outcome in agreement with our data presented here. Additionally, differential expression of PPARα, PPARγ1, and PPARγ2 in different immune cell populations in NOD mice has also been reported (Yaacob et al. 2009 ). In this study, the expression of PPARγ2 was impaired in macrophages and in CD4 T cells of NOD mouse at three different stages of diabetes development (Yaacob et al. 2009 ). Additionally, these investigators showed that expression of PPARα was significantly lower in peritoneal macrophages in diabetic mice (Yaacob et al. 2009 ), again in agreement with our data suggesting a crucial role of the PPAR family in pathogenesis of diabetes. The presence of multiple Stat DNA-binding consensus sequences within the regulatory regions of three important genes related to diabetes development suggests that cross talk exists between the Jak-Stat signaling pathway and these genes. However, understanding genetic interactions among the Jak-Stat signaling pathway and PPAR family, along with adiponectin, appears to be of importance for future investigations. The application of rosiglitazone alone and in combination with Tyrphostin AG490 markedly blocked phosphorylation of Stat5 and increased the truncated form of this important transcription factor (see Fig. 5 ), thereby further inhibiting the transcription machinery of this protein (DavoodiSemiromi et al. 2007a ). Furthermore, we have demonstrated that at mRNA and protein level, inactivation of the Jak-Stat signaling pathway by Tyrphostin AG490 possesses antidiabetic properties, and this is at least achieved via upregulation of transcription factor C/EBP and adiponectin which is known to have antidiabetic properties. Our gel-shift experiments further support this notion that these genes can actually be regulated by the Jak-Stat pathway; however, replication of the same data using total or nuclear protein extracted from adipocytes or adipose tissues awaits to be seen.
Taken together, the presence of the Stat5 DNA-binding consensus sequences within the promoter region of three important diabetes-associated factors further emphasize the potential importance of the Jak-Stat signaling pathway in pathogenesis of diabetes. In addition, appropriate blocking of this signaling pathway may have broad implications for the prevention and/or treatment of several diseases. Fig. 5 The effects of rosiglitazone and Tyrphostin AG490 on phosphorylation of STAT3 and STAT5 in SGBS. a Differentiated adipocytes were left untreated (control) and/or were treated with rosiglitazone and or a combination of rosiglitazone plus Tyrphostin AG490 for 0.5 and 16 h (overnight). Ten micrograms of total protein was loaded onto 10 % acrylamide SDS gel, and the membrane-bound protein was initially hybridized with anti-phosphorylated antibody and then rehybridized with antipan antibody of the same protein. The membrane finally was hybridized with anti-actin antibody to prove equal protein loading in each well. b Densitometry of activated Stat5 (full length), and total Stat5 was measured and normalized based on the control. This represents one of two independent experiments with the same results. Rosi, rosiglitazone; FL, full length; Trn, truncated
